PPCB Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026
Revenue
0
0
0
Cost of Revenue
0
0
0
Gross Profit
0
0
0
Operating Expenses
6.4M
+75.1%
3.7M
-21.8%
4.7M
R&D
169.7K
+750.0%
20.0K
-66.8%
60.2K
SG&A
6.2M
+71.4%
3.6M
-21.2%
4.6M
Operating Income
-6400221
-75.1%
-3654734
+21.8%
-4673564
EBITDA
-6399905
-75.1%
-3654505
+21.8%
-4673439
Net Income
-6360336
-105.7%
-3091394
+36.1%
-4837738
EPS (Basic)
$-0.28
+96.3%
$-7.50
+23.1%
$-9.75
EPS (Diluted)
$-0.28
+96.3%
$-7.50
+23.1%
$-9.75
Shares (Diluted)
22.4M
+4096.6%
534.4K
+8.3%
493.3K
Propanc Biopharma (PPCB) โ€” Financials